437 results on '"Kipps, T J"'
Search Results
2. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia
3. Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia
4. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
5. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
6. Wnt5a induces ROR1 to associate with 14–3–3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells
7. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells
8. P669: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 3-YEAR FOLLOW-UP FROM THE PHASE 2 CAPTIVATE STUDY FD COHORT
9. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
10. Results from the international, randomized phase 3 study of ibrutinib versus chlorambucil in patients 65 Years and older with treatmentnaïve (TN) CLL/SLL (RESONATE-2TM): 4
11. EBV-Associated B-Cell Lymphomas Following Transfer of Human Peripheral Blood Lymphocytes to Mice with Severe Combined Immune Deficiency
12. Updated efficacy including subgroup analyses and safety in the phase 3 RESONATETM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukaemia/small lymphocytic lymphoma: 35
13. Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia
14. Trisomy 12 CLLs progress through NOTCH1 mutations
15. FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 7‐YEAR RESULTS FROM RESONATE‐2
16. CAPTIVATE PRIMARY ANALYSIS OF FIRST‐LINE TREATMENT WITH FIXED‐DURATION IBRUTINIB PLUS VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)
17. Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression
18. Laser microdissection for the assessment of the clonal relationship between chronic lymphocytic leukemia/small lymphocytic lymphoma and proliferating B cells within lymph node pseudofollicles
19. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154
20. Trisomy 12 chronic lymphocytic leukaemia cells exhibit functional upregulation of integrin signalling that is modulated by NOTCH1 mutations: 38
21. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia
22. The CLLU1 expression level is a stable and inherent feature of the chronic lymphocytic leukemia clone
23. Chimeric form of tumor necrosis factor-α has enhanced surface expression and antitumor activity
24. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia
25. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia
26. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma
27. Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference
28. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia
29. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation
30. Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL)
31. Measurement of CLLU1 can monitor for minimal residual disease in patients with chronic lymphocytic leukemia after therapy: V92
32. Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia
33. Signal transduction pathways and mechanisms of apoptosis in CLL B-lymphocytes: their role in CLL pathogenesis
34. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
35. Genetic dynamics in untreated CLL patients with either stable or progressive disease: A longitudinal study
36. CXCR4 chemokine receptors target small cell lung cancer metastasis to the bone marrow: 485
37. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
38. Erratum: Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression
39. Elements of the Human Immune System: Studies of Mature Lymphoid Cells Following Xenotransplantation to Scid Mice
40. Fluorescence-Activated Cell Sorter and Monoclonal Antibodies: Complementary Tools in Immunodiagnosis and Immunotherapy
41. Erratum: Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia
42. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
43. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
44. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib
45. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia
46. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
47. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
48. AN EVALUATION OF THE CLL-IPI SCORE AND COMPREHENSIVE PROGNOSTIC FACTOR ANALYSIS IN PATIENTS WITH R/R CLL IN IDELALISIB PHASE 3 RANDOMIZED STUDIES
49. Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
50. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.